Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,023 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study.
Wang S, Chao J, Wang H, Li S, Wang Y, Zhu C, Zhang N, Piao M, Yang X, Liu K, Xun Z, Sang X, Yang X, Duan W, Zhao H. Wang S, et al. Among authors: sang x. Cancer Immunol Immunother. 2024 Oct 3;73(12):249. doi: 10.1007/s00262-024-03841-z. Cancer Immunol Immunother. 2024. PMID: 39358645 Free PMC article.
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Mao J, et al. Among authors: sang x. J Immunother Cancer. 2021 Dec;9(12):e003334. doi: 10.1136/jitc-2021-003334. J Immunother Cancer. 2021. PMID: 34873013 Free PMC article.
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F, Chen B, Yang X, Wang H, Zhang G, Wang Y, Wang Y, Zhang N, Xue J, Long J, Li Y, Sun H, Xun Z, Liu K, Chen X, Song Y, Yang X, Lu Z, Mao Y, Sang X, Lu Y, Zhao H. Xie F, et al. Among authors: sang x. Front Immunol. 2022 Dec 9;13:1052937. doi: 10.3389/fimmu.2022.1052937. eCollection 2022. Front Immunol. 2022. PMID: 36569829 Free PMC article.
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H. Yang X, et al. Among authors: sang x. Hepatol Int. 2023 Jun;17(3):709-719. doi: 10.1007/s12072-022-10480-y. Epub 2023 Feb 8. Hepatol Int. 2023. PMID: 36753026 Free PMC article.
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Zhu C, Li H, Yang X, Wang S, Wang Y, Zhang N, Wang Y, Xue J, Zhang L, Ning C, Yang X, Xun Z, Chao J, Long J, Sang X, Zhu Z, Zhao H. Zhu C, et al. Among authors: sang x. Cancer Immunol Immunother. 2023 Sep;72(9):2949-2960. doi: 10.1007/s00262-023-03466-8. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37247023 Free PMC article.
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X, Lian B, Zhang N, Long J, Li Y, Xue J, Chen X, Wang Y, Wang Y, Xun Z, Piao M, Zhu C, Wang S, Sun H, Song Z, Lu L, Dong X, Wang A, Liu W, Pan J, Hou X, Guan M, Huo L, Shi J, Zhang H, Zhou J, Lu Z, Mao Y, Sang X, Wu L, Yang X, Wang K, Zhao H. Yang X, et al. Among authors: sang x. BMC Med. 2024 Jan 29;22(1):42. doi: 10.1186/s12916-024-03257-7. BMC Med. 2024. PMID: 38281914 Free PMC article.
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Wang S, Wang Y, Zhu C, Liu K, Chao J, Zhang N, Piao M, Yang X, Zhang L, Long J, Xun Z, Zhang T, Sang X, Yang X, Zhao H. Wang S, et al. Among authors: sang x. Int J Surg. 2024 Aug 1;110(8):4608-4616. doi: 10.1097/JS9.0000000000001540. Int J Surg. 2024. PMID: 38704621 Free PMC article.
1,023 results